The therapeutic candidate is under development for the treatment of ovarian cancer. It comprises of induced pluripotent stem (iPS) cell derived natural killer (iNK) cell.

Human Amniotic Epithelial Stem Cells is under clinical development by iCELL Biotechnology and currently in Phase I for Parkinson's Disease.

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...

Dr. Sunita Tandulwadkar’s journey is a testament to her relentless pursuit of excellence, innovation, and service.

The Abu Dhabi Stem Cells Center ADSCC has successfully performed four testicular tissue cryopreservation TTC procedures on ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

At Mayo Clinic, researchers published more than 10,000 scientific papers in 2024 that are driving medical discoveries, ...

Born in the Santa Isabel Clinic in Lima, Peru, a baby has been born using a new technique called Fertilo. This uses ovarian ...

The research team has embarked on developing a cell-based artificial ovary that can safely supplement female hormones and replace hormone drug therapy. After isolating the cells that produce ...

While gene therapy has emerged as a promising alternative for treating beta-thalassemia, hematopoietic stem cell ...

The findings are published in the journal Cancer Cell. The number of immune cells in a tumor has been shown to affect how patients respond to treatment ... same results in ovarian cancer.

R3 new logo R3 Stem Cell is offering highest grade immunotherapy with Natural Killer Cells in Tijuana Mexico. The immu ...